Abstract
The concept of a “magic bullet” as first formulated by Paul Ehrlich can perhaps most readily be applied to antibodies “armed” with toxic substances or radionuclides. Most of the toxins from plants and bacteria are enzymes, a single molecule of which can catalyze thousands of reactions. In contrast, non-enzymatic reagents must be potent enough that only a few molecules are able to damage vital structures such as DNA and microtubules. Most of the current ADCs bind to the tubulin subunit of microtubules, which are the major components of the mitotic spindle, and inhibit their function in the process of cell division. Rapidly dividing cells such as tumor cells become stranded in the pre-mitotic phase of the cell cycle and eventually die. To equip antibodies with a radioactive payload, they are conjugated with cage-like complexes (chelators) that bind the positively charged ions of radioactive metals. In more recent approaches to diminish side effects, the antibody-chelate conjugates have been loaded with radionuclides after binding their target molecules in the tumor tissue.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Selected Literature
Akhavan D, Yazaki P, Yamauchi D, et al. Phase I study of Yttrium-90 radiolabeled M5A anti-carcinoembryonic antigen humanized antibody in patients with advanced carcinoembryonic antigen producing malignancies. Cancer Biother Radiopharm. 2020;35(1):10–5. https://doi.org/10.1089/cbr.2019.2992.
Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody structure and function: the basis for engineering therapeutics. Antibodies. 2019;8(4):55. https://doi.org/10.3390/antib8040055.
Conlon KC, Miljkovic MD, Waldmann TA. Cytokines in the treatment of cancer. J Interf Cytokine Res. 2019;39(1):6–21. https://doi.org/10.1089/jir.2018.0019.
Goldenberg DM, Sharkey RM. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. Expert Opin Biol Ther. 2020;20(8):871–85. https://doi.org/10.1080/14712598.2020.1757067.
Guerrero-Ochoa P, Aguilar-Machado D, Ibáñez-Pérez R, et al. Production of a granulysin-based, Tn-targeted cytolytic immunotoxin using pulsed electric field technology. Int J Mol Sci. 2020;21(17):6165. https://doi.org/10.3390/ijms21176165.
Hagerty BL, Pegna GJ, Xu J, et al. Mesothelin-targeted recombinant immunotoxins for solid tumors. Biomol Ther. 2020;10(7):973. https://doi.org/10.3390/biom10070973.
Hedrich WD, Fandy TE, Ashour HM, Wang H, Hassan HE. Antibody-drug conjugates: pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned. Clin Pharmacokinet. 2018;57(6):687–703. https://doi.org/10.1007/s40262-017-0619-0.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, et al. Tumor immunotargeting using innovative radionuclides. Int J Mol Sci. 2015;16:3932–54. https://doi.org/10.3390/ijms16023932.
Kreitman RJ. Hairy cell leukemia: present and future directions. Leuk Lymphoma. 2019;60(12):2869–79. https://doi.org/10.1080/10428194.2019.1608536.
Kreitman RJ, Pastan I. Development of recombinant immunotoxins for hairy cell leukemia. Biomol Ther. 2020;10(8):1140. https://doi.org/10.3390/biom10081140.
Leung D, Wurst JM, Liu T, et al. Antibody conjugates—recent advances and future innovations. Antibodies. 2020;9(1):2. https://doi.org/10.3390/antib9010002.
Makita S, Maruyama D, Tobinai K. Safety and efficacy of brentuximab vedotin in the treatment of classic Hodgkin lymphoma. Onco Targets Ther. 2020;13:5993–6009. https://doi.org/10.2147/OTT.S193951.
Murer P, Neri D. Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. New Biotechnol. 2019;52:42–53. https://doi.org/10.1016/j.nbt.2019.04.002.
Norsworthy KJ, Ko CW, Lee JE, et al. FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist. 2018;23(9):1103–8. https://doi.org/10.1634/theoncologist.2017-0604.
Ponziani S, Di Vittorio G, Pitari G, et al. Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci. 2020;21:5510. https://doi.org/10.3390/ijms21155510.
Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451–8. https://doi.org/10.4049/jimmunol.1490019.
Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–600. https://doi.org/10.1200/JCO.19.01140.
Sachpekidis C, Jackson DB, Soldatos TG. Radioimmunotherapy in non-Hodgkin’s lymphoma: retrospective adverse event profiling of Zevalin and Bexxar. Pharmaceuticals. 2019;12(4):141. https://doi.org/10.3390/ph12040141.
Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy. 2011;3:349–70.
Sharma SK, Bagshawe KD. Antibody directed enzyme prodrug therapy (ADEPT): trials and tribulations. Adv Drug Deliv Rev. 2017;118:2–7.
Shim H. Bispecific antibodies and antibody-drug conjugates for cancer therapy: technological considerations. Biomol Ther. 2020;10(3):360. https://doi.org/10.3390/biom10030360.
Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117(12):1736–42. https://doi.org/10.1038/bjc.2017.367.
Sutamtewagul G, Link BK. Novel treatment approaches and future perspectives in follicular lymphoma. Ther Adv Hematol. 2019;10:1–20. https://doi.org/10.1177/2040620718820510.
Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33–46.
Verhoeven M, Seimbille Y, Dalm SU. Therapeutic applications of pretargeting. Pharmaceutics. 2019;11(9):434. https://doi.org/10.3390/pharmaceutics11090434.
Zhang Y, Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res. 2008;14:7981–6.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Little, M. (2021). Antibodies as Magic Bullets. In: Antibodies for Treating Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-72599-0_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-72599-0_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-72598-3
Online ISBN: 978-3-030-72599-0
eBook Packages: MedicineMedicine (R0)